Displaying 46 - 50 of 50
Thu 24 May 2012
The Scottish Medicines Consortium (SMC) has approved everolimus (Afinitor®) for use within NHS Scotland in the treatment of neuroendocrine pancreatic cancer in adults with progressive disease.Read More about 'SMC approves drug for the treatment of neuroendocrine pancreatic cancer'
Wed 12 October 2011
Macmillan's research provides further evidence of how badly people with pancreatic cancer fare compared to other cancer patients.Read More about 'The Cancer Survival Lottery'
Wed 07 September 2011
Outcomes for pancreatic cancer patients in the UK fall well below acceptable levels according to Pancreatic Cancer UK's Study for Survival. By launching the Campaign for Hope, Pancreatic Cancer UK is setting an ambitious goal to double survival rates for UK pancreatic cancer patients within five years.Read More about 'Pancreatic Cancer UK launch Campaign For Hope'